Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
PMID: 30928089
2019
Journal of pharmacological sciences
Abstract: RESULTS: 103 cases were successfully amplified, and the main drug resistance mutations in the reverse transcriptase (RT) region were M184V (50.49%), K103N (28.16%), Y181C (25.24%), and K65R (27.18%), while no drug main resistance mutation was found in the protease (PR) region.
Surveillance of transmitted HIV drug resistance among newly diagnosed, treatment-naive individuals at a county HIV clinic in Santa Clara County.
Discussion: Further, a review of K65R suggested that the mutation is uncommon, and individuals infected with subtype C HIV may be at a greater risk of acquiring the mutation.
Discussion: Interestingly, we would expect the subsequent appearance of TDF/FTC-associated mutations, but we only observed one case of M184V in 2006 and zero cases of K65R, which are major NRTI mutations selected for by FTC/3TC and TDF, respectively.
Discussion: This may be due to the lower selectivity of FTC for M184V and the inhibitive action of M184V and K65R on viral fitness.
Discussion: Unfortunately, we were unable to fully characterize the HIV subtypes of our study sample, so it is unclear if the absence of K65R in our
HIV Drug Resistance after Failure of 6 Month First-line Therapy in a Hospital: A Case Series.
Abstract: The common NRTI mutations were M184VI and K65R, while NNRTI mutations were Y181CFGVY, K103N, A98AG, E138GQ and G190AGS.
Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda.
PMID: 31257432
2019
The Journal of antimicrobial chemotherapy
Result: The most prevalent NRTI mutations were M184V/I (53.6%), K65R (17.5%) and thymidine analogue mutations (TAMs) were present in 21.6% of VF cases.
Discussion: The K65R mutation, which is selected by lamivudine and tenofovir, was highly prevalent among VF cases in our study, which indicates the prolonged use of lamivudine and tenofovir in this setting.
Discussion: The rampant prevalence of the M184V/I and K65R mutations may not warrant the discontinuation of NRTI usage because these mutations confer increased susceptibility to zidovudine (a second-line regimen component in Uganda) and reduced virological fitness to HIV.
HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: Implications for elimination of mother-to-child transmission.
HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting.
PMID: 31117863
2019
Journal of the International Association of Providers of AIDS Care
Table: K65R
An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors.
PMID: 31109980
2019
Antimicrobial agents and chemotherapy
Abstract: A supplementary analysis for HIV-1 reverse transcriptase inhibitors identified a lower genetic barrier for K65R in subtype C through differential codon usage not reported before.
HIV-1 Reverse Transcriptase Promotes Tumor Growth and Metastasis Formation via ROS-Dependent Upregulation of Twist.
PMID: 31885806
2019
Oxidative medicine and cellular longevity
Method: Mutations M184V and K65R conferring resistance to nucleoside RT inhibitors (NRTI) and K103N and G190S conferring resistance to nonnucleoside RT inhibitors (NNRTI) were introduced into p6HRT_A by site-directed mutagenesis (Evrogen) generating plasmids p6HRT_An (65/184) and p6HRT_Ann (103/190), respectively.
Result: Based on this, we designed RT_A with M184V and K65R/N (RT_An) and RT_A with K103N and G190S (RT_Ann) which we predicted to have reduced polymerase and RNase H activities, respectively.
Result: Mutatio
[Postmortem Molecular Epidemiology of HIV-1 Strains Isolated in Turkey].
HIV mutation literature information.
PMID: 
2019
Journal of pharmacological sciences
Browser Board
Co-occurred Entities
Filtrator
ViMRT